Results 91 to 100 of about 4,153 (212)

Efficacy and safety of finerenone in individuals with type 2 diabetes mellitus complicated by diabetic kidney disease: A retrospective observational study

Metabolism Open
Aim/introduction: Early therapeutic interventions are necessary to reduce cardiovascular and renal composite endpoints in individuals with type 2 diabetes mellitus (T2DM) and diabetic kidney disease (DKD).
Yuji Kawaguchi, Yuriko Hajika, Narumi Ashida, Maho Rinka, Chie Hamai, Koji Masumoto, Jun Sawa, Kenji Hamazaki, Yasuro Kumeda   +8 more
doaj   +1 more source

Advances in the Development of Non-steroidal Mineralocorticoid-receptor Antagonists [PDF]

, 2019
The mineralocorticoid receptor (MR) belongs to the nuclear receptor superfamily and regulates body fluid and electrolyte balance. In the last years, much effort has been put into the development of non-steroidal MR antagonists that overcome the side ...
de la Rosa, Diego Alvarez, de Vega, Maria Jesús Pérez, Gerona-Navarro, Guillermo, González-Muñiz, Rosario, Martín-Martínez, Mercedes, Pérez-Gordillo, Felipe L., Rodríguez, Yoel   +6 more
core   +2 more sources

Huangkui capsule combined with finerenone attenuates diabetic nephropathy by regulating the JAK2/STAT3 signaling pathway based on network pharmacology, molecular docking, and experimental verification

Frontiers in Pharmacology
IntroductionDiabetic nephropathy (DN) is a serious complication of diabetes with limited therapeutic options. Although Huangkui capsule (HKC) and finerenone individually show potential in DN management, their combined mechanism remains unclear.
Xuanke Liu, Chunjiang Zhang, YanJie Fu, JingJing Dai, Jiaying Lu, Gang Liu, Xiaoping Yang   +6 more
doaj   +1 more source

Design and rationale of FINE-REAL: A prospective study of finerenone in clinical practice [PDF]

, 2023
AIMS: Contemporary patterns of care of patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) and the adoption of finerenone are not known.
Desai, Nihar R, Gay, Alain, Hamacher, Stefanie, Navaneethan, Sankar D, Nicholas, Susanne B, Pantalone, Kevin M, Wanner, Christoph, Wheeler, David C   +7 more
core  

Finerenone in the management of diabetes kidney disease [PDF]

BMC Nephrology
People with type 2 diabetes are at risk of developing progressive diabetic kidney disease (DKD) and end stage kidney failure. Hypertension is a major, reversible risk factor in people with diabetes for development of albuminuria, impaired kidney function, end-stage kidney disease and cardiovascular disease.
De, Parijat, Khine, May T, Frankel, Andrew, Goldet, Gabrielle, Banerjee, Debasish, Montero, Rosa M, Chowdhury, Tahseen A, Fogarty, Damien, Karalliedde, Janaka; id_orcid 0000-0002-2617-8320, Mallik, Ritwika, Patel, Dipesh C, Wahba, Mona, Winocour, Peter, Zac-Varghese, Sagen, Bain, Stephen, Sharif, Adnan, Bellary, Srikanth, Dasgupta, Indranil   +17 more
openaire   +5 more sources

Finerenone: Fiddling With Hyperkalemia? [PDF]

American Journal of Kidney Diseases, 2021
Joshua Waitzman, Mark Canney, Swapnil Hiremath   +2 more
openaire   +2 more sources

Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background The mineralocorticoid receptor plays a significant role in the development of chronic kidney disease (CKD) and associated cardiovascular complications.
Ixchel Lima Posada, Matthieu Soulié, Yohan Stephan, Roberto Palacios Ramirez, Benjamin Bonnard, Lionel Nicol, Bertram Pitt, Peter Kolkhof, Paul Mulder, Frederic Jaisser   +9 more
doaj   +1 more source

Finerenone and Outpatient Worsening Heart Failure with Mildly Reduced or Preserved Ejection Fraction:A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial [PDF]

Importance: Worsening heart failure (HF) is commonly managed in the outpatient setting with adjustments in oral diuretic therapy. The effect of the nonsteroidal mineralocorticoid receptor antagonist finerenone on outpatient worsening HF events in ...
Brinker, Meike, Chatur, Safia, Claggett, Brian L., Cunningham, Jonathan W., Desai, Akshay S., Jhund, Pardeep S., Kim, So Young, Lam, Carolyn S.P., Lay-Flurrie, James, Llamas Esperón, Guillermo, McMurray, John J.V., Pitt, Bertram, Rohwedder, Katja, Sato, Naoki, Senni, Michele, Shah, Sanjiv, Solomon, Scott D., Vaduganathan, Muthiah, Viswanathan, Prabhakar, Voors, Adriaan, Zannad, Faiez, Zieroth, Shelley   +21 more
core   +1 more source

Meta-analysis of the Efficacy and Safety of Finerenone in the Treatment of Type 2 Diabetic Nephropathy [PDF]

Zhongguo quanke yixue
Background Finerenone, a nonsteroidal mineralocorticoid antagonist, is a novel therapeutic agent for renal protection in patients with diabetic kidney disease, joining the ranks of angiotensin-converting enzyme inhibitors and sodium-glucose cotransporter
ADILI Tuersun, CHENG Gang
doaj   +1 more source

Finerenone and Kidney Outcomes in Patients With Heart Failure:The FINEARTS-HF Trial [PDF]

Background: Finerenone has kidney-protective effects in patients with chronic kidney disease with type 2 diabetes, but effects on kidney outcomes in patients with heart failure with and without diabetes and/or chronic kidney disease are not known ...
Brinker, Meike, Claggett, Brian L., Desai, Akshay S., Henderson, Alasdair D., Jhund, Pardeep S., Kulac, Ian J., Lam, Carolyn S.P., Mc Causland, Finnian R., McMurray, John J.V., Perkins, Robert, Pitt, Bertram, Scheerer, Markus F., Schloemer, Patrick, Senni, Michele, Shah, Sanjiv J., Solomon, Scott D., Vaduganathan, Muthiah, Voors, Adriaan A., Zannad, Faiez   +18 more
core   +2 more sources